Masatoshi Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Masatoshi Ito has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Takehiko Okuno
Department of Pediatrics, Shiga Medical Center for Children, Moriyama
2 shared publicationsTatsuya Fujii
Department of Pediatrics, Shiga Medical Center for Children, Moriyama
2 shared publicationsAkihisa Mitsudome
Department of Pediatrics, School of Medicine, Fukuoka University, Fukuoka
1 shared publicationHiromi Iwata
Department of Pediatrics, School of Medicine, Fukuoka University, Fukuoka
1 shared publicationKenichiro Kobayashi
Department of Pediatrics, Shiga Medical Center for Children, Moriyama
1 shared publication- Shinichi Hirose
General Medical Research Center School of Medicine, Fukuoka University, 45-1 7-chome Nanakuma Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan
1 shared publication
Latest Publications
- Open Access
Electroclinical Picture of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy in a Japanese Family
Summary: Purpose: Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is the first described partial epilepsy syndrome known to be due to a single gene mutation. We found a first Japanese ADNFLE family with a novel mutation of the neuronal nicotinic acetylcholine receptor (nAChR) α4 subunit (CHRNA4) gene. The aim of this report is precisely to describe the electroclinical manifestations of ADNFLE in this family and to compare these findings with those of other families reported previously in the literature. Methods: Three affected family members were investigated electroclinically by close clinical observation, interictal EEG, video‐EEG monitoring, magnetic resonance imaging, and single‐photon‐emission tomography. Information about other affected family members was obtained from either the spouse or the parents. Mutations within the CHRNA4 gene were examined in seven family members. Results: The clinical manifestations and diagnostic findings in the members of this family were consistent with ADNFLE. However, there were intrafamilial and interfamilial variations in clinical features. The seizures of the patients were brief tonic seizures, with hyperventilation in children and secondarily generalized tonic–clonic convulsions in adults. The onset of the children's seizures began in infancy and early childhood. The children's seizures were sometimes provoked by movement and sound stimulation, and did not respond to antiepileptic drugs. On the other hand, the adults’ seizures disappeared spontaneously or were easily controlled with carbamazepine. Three children showed hyperactivity, and two children had mild mental retardation. All patients had impaired consciousness during their seizures and no auras. A novel missense mutation (c755C>T) in exon 5 of the CHRNA4 gene was found in four affected family members. Conclusions: The electroclinical pictures of a Japanese family with ADNFLE were basically the same as those of other families reported, but with slight differences. ADNFLE is probably not uncommon, and it is very likely that there are unidentified patients with this inherited disorder in Japan.
Open AccessElectroclinical Picture of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy in a Japanese Family
Summary: Purpose: Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is the first described partial epilepsy syndrome known to be due to a single gene mutation. We found a first Japanese ADNFLE family with a novel mutation of the neuronal nicotinic acetylcholine receptor (nAChR) α4 subunit (CHRNA4) gene. The aim of this report is precisely to describe the electroclinical manifestations of ADNFLE in this family and to compare these findings with those of other families reported previously in the literature. Methods: Three affected family members were investigated electroclinically by close clinical observation, interictal EEG, video‐EEG monitoring, magnetic resonance imaging, and single‐photon‐emission tomography. Information about other affected family members was obtained from either the spouse or the parents. Mutations within the CHRNA4 gene were examined in seven family members. Results: The clinical manifestations and diagnostic findings in the members of this family were consistent with ADNFLE. However, there were intrafamilial and interfamilial variations in clinical features. The seizures of the patients were brief tonic seizures, with hyperventilation in children and secondarily generalized tonic–clonic convulsions in adults. The onset of the children's seizures began in infancy and early childhood. The children's seizures were sometimes provoked by movement and sound stimulation, and did not respond to antiepileptic drugs. On the other hand, the adults’ seizures disappeared spontaneously or were easily controlled with carbamazepine. Three children showed hyperactivity, and two children had mild mental retardation. All patients had impaired consciousness during their seizures and no auras. A novel missense mutation (c755C>T) in exon 5 of the CHRNA4 gene was found in four affected family members. Conclusions: The electroclinical pictures of a Japanese family with ADNFLE were basically the same as those of other families reported, but with slight differences. ADNFLE is probably not uncommon, and it is very likely that there are unidentified patients with this inherited disorder in Japan.
- 27 June 2000
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (12) , 2346-2347
Subdural hematoma during low-dose ACTH therapy in patients with West syndrome
- 27 June 2000
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (12) , 2346-2347
Subdural hematoma during low-dose ACTH therapy in patients with West syndrome
- 1 June 2000
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 15 (6) , 424-428
Current Therapy for West Syndrome in Japan
We sent questionnaires concerning the current therapy for West syndrome to 208 institutions at which pediatric care members of the Japan Epilepsy Society were working. Of these, 129 (62%) institutions responded. Vitamin B6 was the preferred first-line drug, followed by the combination of vitamin B6 and valproate or mono-therapy with valproate. Corticotropin was the third choice among the drugs. The dosage of corticotropin was lower than previously reported. The treatment of West syndrome is not well established at present and further research is needed to improve the therapeutic protocol. ( J Child Neurol 2000; 15:424-428).
- 1 June 2000
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 15 (6) , 424-428
Current Therapy for West Syndrome in Japan
We sent questionnaires concerning the current therapy for West syndrome to 208 institutions at which pediatric care members of the Japan Epilepsy Society were working. Of these, 129 (62%) institutions responded. Vitamin B6 was the preferred first-line drug, followed by the combination of vitamin B6 and valproate or mono-therapy with valproate. Corticotropin was the third choice among the drugs. The dosage of corticotropin was lower than previously reported. The treatment of West syndrome is not well established at present and further research is needed to improve the therapeutic protocol. ( J Child Neurol 2000; 15:424-428).